Submission of the Annual Report for the FY 2024-25, containing Audited Financial Statements, Auditors Report and Directors Report and the Notice convening 40th Annual General Meeting of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals has submitted its Annual Report for FY 2024-25 to BSE, accompanied by the Notice convening its 40th Annual General Meeting on Friday, 18 July 2025 at 3:30 p.m. via video conferencing. The board has recommended a dividend of ₹18 per share (180%) on equity shares of ₹10 each for FY 2024-25. The Auditor's Report carries an unmodified opinion, and the AGM includes ordinary business (adoption of financials, dividend declaration) along with special business for re-appointing Ashish U. Bhuta as Chairman and Managing Director for five years from 1 April 2026. The company is celebrating 40 years of operations, with its flagship brand Nervijen ranking among the top vitamin/mineral brands in India.
Routine annual filing — no material surprise. A robust 180% dividend signals strong cash generation and shareholder returns, while the clean (unmodified) audit opinion supports continued investor confidence. The re-appointment of the promoter CMD ensures leadership continuity.